Clinical Trials · NCT07325500
Incretin Microdosing for Cardiometabolic Health in People With HIV
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- The University of Texas Health Science Center, Houston
- Enrollment
- 30
- Start date
- Feb 2026
- Locations
- 1 site, United States
- Primary endpoint
- Percent weight regain from weeks 12-60 (microdosing period)